Quoin Pharmaceuticals Ltd (QNRX)
4.33
-0.04 (0.92%)
Upcoming Events
Latest Headlines
Form ARS Quoin Pharmaceuticals, For: Dec 31
July 16, 2026 7:35 AM - SEC Filing
Form DEF 14A Quoin Pharmaceuticals, For: Aug 20
July 16, 2026 7:31 AM - SEC Filing
Quoin gets FDA clearance for Phase 2 trial of QRX003 in rare skin disease
July 9, 2026 8:30 AM - StreetInsider
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
July 9, 2026 8:30 AM - Globe NewsWire
Form PRE 14A Quoin Pharmaceuticals, For: Aug 20
July 6, 2026 5:21 PM - SEC Filing
Quoin Pharmaceuticals receives U.S. patent allowance for Netherton drug
June 30, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
June 30, 2026 8:30 AM - Globe NewsWire
Form 8-K Quoin Pharmaceuticals, For: Jun 23
June 23, 2026 4:16 PM - SEC Filing
FDA conditionally approves QYLEKI as brand name for Quoin drug
June 23, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
June 23, 2026 8:30 AM - Globe NewsWire
Quoin Pharma forms Japan subsidiary to advance QRX003 commercialization
June 18, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
June 18, 2026 8:30 AM - StreetInsider
Quoin Pharmaceuticals reports 4 of 6 patients improved in NS compassionate use trial
June 16, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
June 16, 2026 8:30 AM - Globe NewsWire
ThinkEquity Starts Quoin Pharmaceuticals (QNRX) at Buy
June 15, 2026 6:07 AM - StreetInsider
Form 8-K Quoin Pharmaceuticals, For: Jun 04
June 4, 2026 4:04 PM - SEC Filing
Japan's health ministry grants orphan drug status to Quoin's QRX003
June 4, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
June 4, 2026 8:30 AM - Globe NewsWire
Form SCHEDULE 13G Quoin Pharmaceuticals, Filed by: INTEGRATED CORE STRATEGIES (US) LLC
June 2, 2026 5:14 PM - SEC Filing
Quoin Pharmaceuticals submits IND for rare skin disorder treatment
June 2, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
June 2, 2026 8:30 AM - Globe NewsWire
Form 424B3 Quoin Pharmaceuticals,
June 2, 2026 6:09 AM - SEC Filing
Form SCHEDULE 13G/A Quoin Pharmaceuticals, Filed by: ADAR1 Capital Management, LLC
May 15, 2026 8:16 PM - SEC Filing
Form SCHEDULE 13G/A Quoin Pharmaceuticals, Filed by: Stonepine Capital Management, LLC
May 15, 2026 5:27 PM - SEC Filing
Form SCHEDULE 13G/A Quoin Pharmaceuticals, Filed by: Woodline Partners LP
May 15, 2026 9:13 AM - SEC Filing
Full Article List
